{"id":716,"date":"2021-05-18T14:35:17","date_gmt":"2021-05-18T14:35:17","guid":{"rendered":"https:\/\/alectos.com\/alectos-content\/?page_id=716"},"modified":"2025-04-02T11:15:07","modified_gmt":"2025-04-02T18:15:07","slug":"home","status":"publish","type":"page","link":"https:\/\/alectos.com\/alectos-content\/","title":{"rendered":"Home"},"content":{"rendered":"

Alectos Therapeutics<\/h1><\/div>

Alectos is a leader in the discovery and preclinical development of
\nnovel small-molecule therapeutics to treat neurological diseases<\/p>\n<\/div>

PIPELINE<\/span><\/a><\/div>
OUR SCIENCE<\/span><\/a><\/div><\/div><\/div><\/div>
PIPELINE<\/span><\/a><\/div>
Our Science<\/span><\/a><\/div><\/div><\/div><\/div><\/div>

Who We Are<\/h2><\/div>
<\/div><\/div><\/div><\/div>

Alectos Therapeutics uncovers groundbreaking treatments that target the root biology of neurodegenerative and acute neurological disorders. The company focuses on identifying and developing innovative approaches to tackle complex conditions such as Alzheimer\u2019s disease, Parkinson\u2019s disease, and acute ischemic stroke.<\/p>\n

Alectos’ pipeline is dedicated to developing new therapies for patients affected by these disorders. Our GBA2 program offers a disease-modifying approach aimed at correcting lysosomal dysfunction in neurodegenerative diseases like Parkinson\u2019s disease and Batten disease. Our OGA program presents a neuroprotective strategy designed to counteract cellular stress in the brain. We initially partnered with Merck to pioneer the first clinical OGA inhibitor, but have since repatriated the program. Leveraging our extensive expertise and intellectual property, we are advancing novel OGA inhibitors as potential treatments for Alzheimer\u2019s disease, Parkinson\u2019s disease, acute ischemic stroke, and traumatic brain injury. We welcome partnership inquiries regarding our OGA and GBA2 programs and our advanced preclinical development candidates.<\/p>\n<\/div><\/div><\/div><\/div><\/div>

Development of novel agents as disease<\/i>-modifying\u00a0<\/em>therapies<\/i> for
\nneurological diseases<\/p>\n<\/div><\/div><\/div><\/div><\/div>

News<\/h2><\/div>
<\/div><\/div><\/div><\/div>
\n

O-GlcNAcylation: a pro-survival response to acute stress in the cardiovascular and central nervous systems<\/a><\/h2>

O-GlcNAcylation is a unique monosaccharide modification that is ubiquitously present in numerous nucleoplasmic and mitochondrial proteins. The hexosamine biosynthesis pathway (HBP), which is a key branch of glycolysis, provides the unique sugar donor UDP-GlcNAc for the O-GlcNAc modification. Thus, HBP\/O-GlcNAcylation can act as a nutrient sensor to perceive changes in nutrient levels and trigger O-GlcNAc modifications of functional proteins in cellular (patho-)physiology, thereby regulating diverse metabolic processes. An imbalance in [...]<\/p><\/div><\/div>

<\/div>
Administrator<\/a><\/span><\/span>2025-03-27T13:00:36-07:00<\/span>March 27, 2025<\/span>|<\/span><\/div><\/div><\/article>\n
\n

O-GlcNAcylation and Its Roles in Neurodegenerative Diseases<\/a><\/h2>

As a non-classical post-translational modification, O-linked \u03b2-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation) is widely found in human organ systems, particularly in our brains, and is indispensable for healthy cell biology. With the increasing age of the global population, the incidence of neurodegenerative diseases is increasing, too. The common characteristic of these disorders is the aggregation of abnormal proteins in the brain. Current research has found that O-GlcNAcylation dysregulation is involved in misfolding [...]<\/p><\/div><\/div>

<\/div>
Administrator<\/a><\/span><\/span>2025-03-27T12:55:58-07:00<\/span>March 27, 2025<\/span>|<\/span><\/div><\/div><\/article>\n
\n

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson\u2019s Disease<\/a><\/h2>

AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson\u2019s Disease Alectos to receive a $15 million upfront payment and is eligible to receive potential future development and commercial milestone payments Cambridge, Mass. and Burnaby, British Columbia \u2013 June 6, 2022 \u2013 Biogen Inc. (Nasdaq: BIIB) \u2013 Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and [...]<\/p><\/div><\/div>

<\/div>
Administrator<\/a><\/span><\/span>2022-06-03T12:12:33-07:00<\/span>June 6, 2022<\/span>|<\/span><\/div><\/div><\/article>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-716","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/pages\/716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/comments?post=716"}],"version-history":[{"count":82,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/pages\/716\/revisions"}],"predecessor-version":[{"id":1317,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/pages\/716\/revisions\/1317"}],"wp:attachment":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/media?parent=716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}